Philogen sells distribution rights for Nidlegy to Sun Pharma

30 May 2023

Italian-Swiss biotech Philogen has entered into a licensing agreement leading Indian drugmaker Sun Pharmaceuticals (BSE: 524715) for commercializing Philogen’s specialty product, Nidlegy (daromun), in the territories of Europe, Australia and New Zealand.

Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by privately-held Philogen for the treatment of melanoma and non-melanoma skin cancers.

Terms of the deal provide for Sun Pharma to have exclusive rights to commercialize Nidlegy for indications of skin cancers in the specified regions. Philogen will complete pivotal clinical trials for the product in Europe, pursue marketing authorization with the regulatory authorities and manufacture commercial supplies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK